BBIXF (Bonus BioGroup) Other Stockholders Equity: $16.36 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BBIXF Bonus BioGroup Ltd BBIXF
21 GF Score
Price $0.10
! 3 Warning Signs
View Full Analysis

What is Bonus BioGroup Other Stockholders Equity?

Bonus BioGroup BBIXF 21 Other Stockholders Equity is $16.36 Mil as of Dec. 2025. GuruFocus rates BBIXF with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

Bonus BioGroup's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $16.36 Mil.

Bonus BioGroup's quarterly Other Stockholders Equity increased from Dec. 2024 ($13.50 Mil) to Jun. 2025 ($14.63 Mil) and increased from Jun. 2025 ($14.63 Mil) to Dec. 2025 ($16.36 Mil).

Bonus BioGroup's annual Other Stockholders Equity increased from Dec. 2023 ($11.92 Mil) to Dec. 2024 ($13.50 Mil) and increased from Dec. 2024 ($13.50 Mil) to Dec. 2025 ($16.36 Mil).

Bonus BioGroup Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Bonus BioGroup's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bonus BioGroup Other Stockholders Equity Chart

Bonus BioGroup Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.97 12.06 11.92 13.50 16.36

Bonus BioGroup Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.92 12.13 13.50 14.63 16.36
BBIXF
21GF Score
Bonus BioGroup Ltd BBIXF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bonus BioGroup Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $16.36 Mil mean?
Bonus BioGroup (BBIXF) has a Other Stockholders Equity of $16.36 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bonus BioGroup and its competitors.
Is Bonus BioGroup's Other Stockholders Equity too high?
Bonus BioGroup's current Other Stockholders Equity is $16.36 Mil. Overall, Bonus BioGroup has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Bonus BioGroup's Other Stockholders Equity compare to VRTX and REGN?
Bonus BioGroup's Other Stockholders Equity of $16.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bonus BioGroup and its competitors. Bonus BioGroup's current Other Stockholders Equity is $16.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonus BioGroup stock overvalued right now?
Bonus BioGroup (BBIXF) has a current Other Stockholders Equity of $16.36 Mil. The current Other Stockholders Equity is $16.36 Mil. Bonus BioGroup's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Bonus BioGroup (BBIXF), the current Other Stockholders Equity is $16.36 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bonus BioGroup Business Description

Other Exchanges BONS:Israel
Address Matam Advanced, Technology Park, P.O.B 15143, Haifa, ISR, 31905
Bonus BioGroup Ltd is an clinical-stage biotechnology company developing next-generation therapies for a variety of indications in the regenerative medicine field. Its products products, BonoFill and MesenCure.
21GF Score

Get the complete analysis for BBIXF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price